Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Successful phase III results reported for British Biotech PAF antagonist

Dec. 9, 1996

Cytel to implement new development strategy for HBV vaccine

Dec. 6, 1996

Phase IIa trial on Isis antiinflammatory antisense compound completed

Dec. 5, 1996

Axcan-Schwarz joint venture to market URSO

Dec. 2, 1996

Chugai discloses erythromycins for gastrointestinal disorders

Nov. 27, 1996

OraVax and Pasteur-Merieux Connaught license H. pylori genome sequence

Nov. 26, 1996

Lilly claims 5-HT7 antagonist for GI indications

Nov. 26, 1996

New market introduction for proton pump inhibitor

Nov. 26, 1996

Neose reports promising phase I results for novel antiulcer drug

Nov. 25, 1996

PDL anti-HBV antibody enters phase II

Nov. 22, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.